Press Releases

Global Market For Rnai Drug Delivery Technologies To Be Worth $24 Billion In 2015

July 18, 2011

Additional Reports


Wellesley, Mass. – In a recent release, RNAI DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS (BIO076A) from BCC Research (, the global market for RNAi (ribonucleic acid interference) drug delivery technologies was valued at $7 billion in 2010. That value is projected to reach $24 billion in 2015, after increasing at a five-year compound annual growth rate (CAGR) of 27.9%.

The RNAi drug delivery market can be broken down into three segments by delivery type – nanoparticle, nucleic acid, and aptamer delivery.

In 2010, the value of the nanoparticle delivery segment was $6.8 billion, and in 2015 that value is expected to reach $21.1 billion, yielding a CAGR of 25.4%.

The nucleic acid delivery segment was valued at $169 million in 2010, and in 2015 should reach a value of nearly $1.1 billion, a CAGR of 45.4%.

The aptamer delivery segment, valued at $49 million in 2010, should be worth nearly $1.9 billion in 2015, growing at a CAGR of 106.8%.

RNA interference allows scientists to silence the expression or effect of a gene being studied. Since the Nobel-prize-winning discovery of RNAi in 1998, the naturally occurring effect of RNAi has been hailed by many as the hottest technical breakthrough in modern biological research.

The RNAi field has rapidly emerged as a fast-growing new market. One of the main reasons for RNAi’s popularity stems from its utility as a molecular biology tool enabling the in vivo functional analysis of thousands of genes. Numerous companies have sprung up capitalizing on the RNAi phenomenon. Pharmaceutical and biotechnology companies in particular are looking at RNAi as a key drug discovery tool, and the RNAi market can expect to see collaborations, mergers, alliances, and licensing starting to flourish within the next five years.

This report will be crucial to companies and firms seeking engagement in the RNAi sector. Others that will find it useful include existing pharmaceutical and biotechnology companies, those involved with RNA research, and operations, sales, and marketing managers within the field or looking to enter it.

To Contact us, click here  help

Source: BCC Research

RNAi Drug Delivery: Technologies and Global Markets( BIO076A )
Publish Date: Jan 2011    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: as the source and publisher. Thank you.